TY - JOUR
T1 - Concurrent radiochemotherapy in the treatment of locally advanced non-small cell lung cancer
AU - Jeremic, Branislav
AU - Machtay, Mitchell
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2004/2
Y1 - 2004/2
N2 - Current evidence suggests that concurrent RT/CHT is the standard of treatment in patients with locally advanced, inoperable NSCLC. This treatment approach, however, bears risk of increased toxicity and, therefore, must be carefully balanced regarding the choice of patients suitable for such an intervention. Newer RT technologies, third-generation CHT drugs, and widely used radioprotectors represent the current framework for numerous clinical studies that ultimately will help optimize the treatment of this disease.
AB - Current evidence suggests that concurrent RT/CHT is the standard of treatment in patients with locally advanced, inoperable NSCLC. This treatment approach, however, bears risk of increased toxicity and, therefore, must be carefully balanced regarding the choice of patients suitable for such an intervention. Newer RT technologies, third-generation CHT drugs, and widely used radioprotectors represent the current framework for numerous clinical studies that ultimately will help optimize the treatment of this disease.
UR - http://www.scopus.com/inward/record.url?scp=1042275581&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1042275581&partnerID=8YFLogxK
U2 - 10.1016/S0889-8588(03)00139-4
DO - 10.1016/S0889-8588(03)00139-4
M3 - Review article
C2 - 15005283
AN - SCOPUS:1042275581
SN - 0889-8588
VL - 18
SP - 91
EP - 100
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 1
ER -